EnteroMedics
ETRM
ETRM was delisted on the 20th of October, 2017.
1 hedge funds and large institutions have $3.33M invested in EnteroMedics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
1,470% more capital inflows, than outflows
Capital inflows: $4.52M | Capital outflows: $288K
30.2% more ownership
Funds ownership: 2.37% → 32.58% (+30%)
93% less funds holding
Funds holding: 14 → 1 (-13)
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SV Health Investors
Boston,
Massachusetts
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$119K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$47K |
| 3 |
D.E. Shaw & Co
New York
|
-$33K |
| 4 |
BlackRock
New York
|
-$31K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$29K |
ETRM Hedge Fund Activity: Q4 2017 in Review
1 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in EnteroMedics (ETRM) for Q4 2017, worth a combined $3.33M — up 1,057% from $288K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ETRM and 1 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was SV Health Investors, opening a new position worth an estimated $4.52M. The largest seller was Vanguard Group, exiting entirely with an estimated $119K sold.
- 1 institutional investor held EnteroMedics (ETRM) as of Q4 2017, down from 14 in Q3 2017.
- Funds reported $3.33M of EnteroMedics stock for Q4 2017, up 1,057% quarter-over-quarter.
- 1 fund opened new EnteroMedics positions in Q4 2017 and 14 closed out, a net change of -13 holders.
- The largest EnteroMedics buyer in Q4 2017 was SV Health Investors, an estimated $4.52M added.
- The largest EnteroMedics seller in Q4 2017 was Vanguard Group, an estimated $119K sold.
Based on aggregated 13F filings for Q4 2017.